Search This Blog

Tuesday, July 28, 2020

Unity Biotech up as Roth starts with 297% upside

Unity Biotechnology (NASDAQ:UBX) finished after-hours trading up 8.3% after an initiation by Roth Capital at Buy.
The firm’s launching coverage with a $35 price target – a new Street-high target implying 297% upside.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)